AstraZeneca has announced plans to purchase the rare disease drug maker Caelum Biosciences in a deal worth up to $500m. The move is part of AZ's ongoing strategy to focus on rare disease drugs.
Join our network of executives who receive the MBS News daily, as well as the insights, analysis and our weekly column in The Weekend Edition.
You’ll be able to unsubscribe at any time.